Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus in TSC1/TSC2/MTOR mutated cancer
NCT02201212Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Sep 2014
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of everolimus in advanced cancer, sponsored by Dana-Farber Cancer Institute. Started Sep 2014; status: completed.
02
Drugs
everolimus
03
Conditions
advanced cancer
Beyond the preview
Go deeper on NCT02201212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02201212.